Lumakras Drug Market By Therapy Type (Monotherapy, Combination Therapy); By Disease Indication (Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Lumakras is a drug that is used to treat adults with non-small cell lung cancer (NSCLC) that has spread and has a mutation (change) in the KRAS gene. It's given to patients who have already had at least one other systemic treatment. According to the American Cancer Society, most lung cancer data include both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for about 13% of all lung cancers, while NSCLC accounts for 84%. Furthermore, the American Society of Clinical Oncology projected that 2.3 million people would be diagnosed with lung cancer worldwide in 2021. In the United States, an estimated 235,760 adults (119,100 men and 116,660 women) were diagnosed with the disease in the same year. Lung cancer is one of the most common cancer and the leading cause of cancer death. This disease is expected to cause deaths of 131,880 people (69,410 men and 62,470 women) in the United States in 2021.
Increasing pipeline medicines related to the lumakras drug is one of the significant factors expected to drive the growth of lumakras drug market over the forecast period. Rising incidence of various cancers, as well as growing popularity of advanced therapies, are fuelling the market growth. Major players are also contributing to market growth through developments. For instance, Mirati Therapeutics, Inc., a clinical-stage targeted oncology corporation, announced positive topline results from the potentially registration-allowing cohort of Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small-cell lung cancer (NSCLC) harboring the KRASG12C mutation consistent with previous systemic therapy, in September 2021. The company intends to publish detailed data from the KRYSTAL-1 study's continuing Phase 2 registration-enabling cohort in previously treated patients with KRASG12C-mutated NSCLC at a medical congress in early 2022.
SARS-CoV-2 (COVID-19) is one of the most serious public health emergencies the civilization has ever seen, with more than 770,000 deaths and immeasurable economic costs. COVID-19 was declared a global pandemic by the World Health Organization on March 12, 2020, as the epidemic condition worsened. In the first half of 2020, the impact of the COVID-19 pandemic on cancer care has led to decreases and delays in detecting new cancers and providing treatment. However, now that the covid-19 illnesses is being handled effectively by economies, key players and the government are focusing more proactively on other diseases, including cancer. The enhanced promise of innovation in cancer therapy showcases potential opportunities for lumakras drug market participants in the healthcare industry to develop in the near future.
Global Lumakras Drug Market Revenue & Forecast, (US$ Million), 2021 – 2030
Therapy Type Outlook:
Based on therapy type, the global lumakras drug market has been primarily segmented into monotherapy and combination therapy. Monotherapy is the use of a single medication to treat a disease or condition in drug therapy. In comparison to polytherapy, monotherapy has been advocated as the optimum epilepsy treatment since it has fewer side effects, no drug interactions, better compliance, cheaper costs, and, in many situations, better seizure control.
Disease Indication Outlook:
Based on disease indication, the global lumakras drug market has been segmented into locally advanced non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer (NSCLC). Locally advanced cancer spreads beyond the body part where it began but has not yet affected other parts of the body. Stage III patients (any T N2-N3M0, T4N0M0, and T3N1M0) and stage II patients (T2B-T3NOM0 and T1-2N1M0) who are unable to undergo a definitive resection due to medical inoperability are included in the locally advanced non-small cell lung cancer stage groupings. As per the international tumor node metastases (TNM) staging system, nearly 30% of patients with non-small cell lung cancer (NSCLC) are diagnosed with "locally advanced" disease. Furthermore, according to the American Society of Clinical Oncology, the overall 5-year survival rate for people with localized NSCLC, which indicate that the cancer has not spread outside of the lung, is 63 percent.
Region Outlook:
North America accounted for the largest share in the global lumakras drug market in 2021 owing to increasing funding for discovery of drugs in this region. Lung cancer is the largest cause of cancer-related death not only in the United States but also globally. According to a study, it has been estimated that in North America, former smokers are more likely to create lung cancer than current smokers. One of the major factors contributing to the region's expansion is an increase in lung cancer incidences. The American Cancer Society estimates that there will be approximately 236,740 new instances of lung cancer in the United States (117,910 in men and 118,830 in women) and approximately 130,180 deaths from lung cancer (68,820 in men and 61,360 in women) in 2022.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of the lumakras drug market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the global lumakras drug market are:
- Amgen Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Mirati Therapeutics, Inc.
- Moderna, Inc.
- Oblique Therapeutics AB
- Revolution Medicines, Inc.
- Silenseed LTD
- Other Market Participants
Global Lumakras Drug Market:
- By Therapy Type
- Monotherapy
- Combination Therapy
- By Disease Indication
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Base
Year: 2021
1.2.2. Forecast
Years: 2022 – 2030
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Lumakras Drug Market
6. Market
Synopsis: Lumakras Drug Market
7. Lumakras
Drug Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Lumakras Drug Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Lumakras Drug Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Lumakras Drug Market
8. Global
Lumakras Drug Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Lumakras Drug Market Revenue (US$ Mn)
8.2. Global
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
8.2.1. Monotherapy
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2021
8.2.1.3. Market
Forecast, 2022 - 2030
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Combination
Therapy
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2021
8.2.2.3. Market
Forecast, 2022 - 2030
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Therapy Type
9. Global
Lumakras Drug Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
9.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2021
9.2.1.3. Market
Forecast, 2022 - 2030
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2021
9.2.2.3. Market
Forecast, 2022 - 2030
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Disease Indication
10. North
America Lumakras Drug Market Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.1.1. North
America Lumakras Drug Market Revenue (US$ Mn)
10.2. North
America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
10.2.1. Monotherapy
10.2.2. Combination
Therapy
10.3. North
America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
10.3.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
10.3.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
10.4. North
America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
10.4.1.1.1. Monotherapy
10.4.1.1.2. Combination
Therapy
10.4.1.2. U.S
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
10.4.1.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
10.4.1.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
10.4.2. Canada
10.4.2.1. Canada
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
10.4.2.1.1. Monotherapy
10.4.2.1.2. Combination
Therapy
10.4.2.2. Canada
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
10.4.2.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
10.4.2.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
10.4.3. Mexico
10.4.3.1. Mexico
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
10.4.3.1.1. Monotherapy
10.4.3.1.2. Combination
Therapy
10.4.3.2. Mexico
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
10.4.3.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
10.4.3.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
10.4.4. Rest of
North America
10.4.4.1. Rest
of North America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
10.4.4.1.1. Monotherapy
10.4.4.1.2. Combination
Therapy
10.4.4.2. Rest
of North America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
10.4.4.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
10.4.4.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Therapy Type
10.5.3. By Disease
Indication
11. Europe
Lumakras Drug Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. Europe
Lumakras Drug Market Revenue (US$ Mn)
11.2. Europe
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.2.1. Monotherapy
11.2.2. Combination
Therapy
11.3. Europe Lumakras
Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.3.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.3.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4. Europe
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.1.1.1. Monotherapy
11.4.1.1.2. Combination
Therapy
11.4.1.2. France
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.4.1.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.1.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.2. The UK
11.4.2.1. The
UK Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.2.1.1. Monotherapy
11.4.2.1.2. Combination
Therapy
11.4.2.2. The
UK Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.4.2.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.2.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.3. Spain
11.4.3.1. Spain
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.3.1.1. Monotherapy
11.4.3.1.2. Combination
Therapy
11.4.3.2. Spain
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.4.3.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.3.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.4. Germany
11.4.4.1. Germany
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.4.1.1. Monotherapy
11.4.4.1.2. Combination
Therapy
11.4.4.2. Germany
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.4.4.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.4.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.5. Italy
11.4.5.1. Italy
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.5.1.1. Monotherapy
11.4.5.1.2. Combination
Therapy
11.4.5.2. Italy
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.4.5.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.5.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.6. Nordic
Countries
11.4.6.1. Nordic
Countries Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.6.1.1. Monotherapy
11.4.6.1.2. Combination
Therapy
11.4.6.2. Nordic
Countries Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
11.4.6.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.6.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.6.3. Nordic
Countries Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux
Union Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.7.1.1. Monotherapy
11.4.7.1.2. Combination
Therapy
11.4.7.2. Benelux
Union Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
11.4.7.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.7.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.4.7.3. Benelux
Union Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The
Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest
of Europe Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
11.4.8.1.1. Monotherapy
11.4.8.1.2. Combination
Therapy
11.4.8.2. Rest
of Europe Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
11.4.8.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
11.4.8.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Therapy Type
11.5.3. By
Disease Indication
12. Asia
Pacific Lumakras Drug Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Asia
Pacific Lumakras Drug Market Revenue (US$ Mn)
12.2. Asia
Pacific Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.2.1. Monotherapy
12.2.2. Combination
Therapy
12.3. Asia
Pacific Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.3.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.3.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4. Asia
Pacific Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1. China
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.1.1.1. Monotherapy
12.4.1.1.2. Combination
Therapy
12.4.1.2. China
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.4.1.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.1.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.2. Japan
12.4.2.1. Japan
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.2.1.1. Monotherapy
12.4.2.1.2. Combination
Therapy
12.4.2.2. Japan
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.4.2.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.2.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.3. India
12.4.3.1. India
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.3.1.1. Monotherapy
12.4.3.1.2. Combination
Therapy
12.4.3.2. India
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.4.3.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.3.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.4. New
Zealand
12.4.4.1. New
Zealand Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.4.1.1. Monotherapy
12.4.4.1.2. Combination
Therapy
12.4.4.2. New
Zealand Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.4.4.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.4.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.5. Australia
12.4.5.1. Australia
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.5.1.1. Monotherapy
12.4.5.1.2. Combination
Therapy
12.4.5.2. Australia
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.4.5.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.5.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.6. South
Korea
12.4.6.1. South
Korea Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.6.1.1. Monotherapy
12.4.6.1.2. Combination
Therapy
12.4.6.2. South
Korea Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.4.6.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.6.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.7. Southeast
Asia
12.4.7.1. Southeast
Asia Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
12.4.7.1.1. Monotherapy
12.4.7.1.2. Combination
Therapy
12.4.7.2. Southeast
Asia Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
12.4.7.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.7.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.4.7.3. Southeast
Asia Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest
of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest
of Asia Pacific Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
12.4.8.1.1. Monotherapy
12.4.8.1.2. Combination
Therapy
12.4.8.2. Rest
of Asia Pacific Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
12.4.8.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
12.4.8.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Therapy Type
12.5.3. By
Disease Indication
13. Middle
East and Africa Lumakras Drug Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Middle
East and Africa Lumakras Drug Market Revenue (US$ Mn)
13.2. Middle
East and Africa Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy
Type
13.2.1. Monotherapy
13.2.2. Combination
Therapy
13.3. Middle
East and Africa Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.3.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.3.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.4. Middle
East and Africa Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi
Arabia Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
13.4.1.1.1. Monotherapy
13.4.1.1.2. Combination
Therapy
13.4.1.2. Saudi
Arabia Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.4.1.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.4.1.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.4.2. UAE
13.4.2.1. UAE
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
13.4.2.1.1. Monotherapy
13.4.2.1.2. Combination
Therapy
13.4.2.2. UAE
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.4.2.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.4.2.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.4.3. Egypt
13.4.3.1. Egypt
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
13.4.3.1.1. Monotherapy
13.4.3.1.2. Combination
Therapy
13.4.3.2. Egypt
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.4.3.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.4.3.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.4.4. Kuwait
13.4.4.1. Kuwait
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
13.4.4.1.1. Monotherapy
13.4.4.1.2. Combination
Therapy
13.4.4.2. Kuwait
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.4.4.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.4.4.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.4.5. South
Africa
13.4.5.1. South
Africa Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
13.4.5.1.1. Monotherapy
13.4.5.1.2. Combination
Therapy
13.4.5.2. South
Africa Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.4.5.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.4.5.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest
of Middle East & Africa Lumakras Drug Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
13.4.6.1.1. Monotherapy
13.4.6.1.2. Combination
Therapy
13.4.6.2. Rest
of Middle East & Africa Lumakras Drug Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
13.4.6.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
13.4.6.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Therapy Type
13.5.3. By
Disease Indication
14. Latin
America Lumakras Drug Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Latin
America Lumakras Drug Market Revenue (US$ Mn)
14.2. Latin
America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
14.2.1. Monotherapy
14.2.2. Combination
Therapy
14.3. Latin
America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.3.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
14.3.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
14.4. Latin
America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
14.4.1.1.1. Monotherapy
14.4.1.1.2. Combination
Therapy
14.4.1.2. Brazil
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.4.1.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
14.4.1.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
14.4.2. Argentina
14.4.2.1. Argentina
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Therapy Type
14.4.2.1.1. Monotherapy
14.4.2.1.2. Combination
Therapy
14.4.2.2. Argentina
Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.4.2.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
14.4.2.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
14.4.3. Rest of
Latin America
14.4.3.1. Rest
of Latin America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.4.3.1.1. Monotherapy
14.4.3.1.2. Combination
Therapy
14.4.3.2. Rest
of Latin America Lumakras Drug Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.4.3.2.1. Locally
Advanced Non-Small Cell Lung Cancer (NSCLC)
14.4.3.2.2. Metastatic
Non-Small Cell Lung Cancer (NSCLC)
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Therapy Type
14.5.3. By
Disease Indication
15. Competitive
Benchmarking
15.1. Market
Share Analysis, 2021
15.2. Global
Presence and Growth Strategies
15.2.1. Mergers
and Acquisitions
15.2.2. Product
Launches
15.2.3. Investments
Trends
15.2.4. R&D
Initiatives
16. Player
Profiles
16.1. Amgen Inc.
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business Strategies
16.2. Boehringer Ingelheim
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business Strategies
16.3. Eli Lilly and Company
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business Strategies
16.4. Mirati Therapeutics, Inc.
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business Strategies
16.5. Moderna, Inc.
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business Strategies
16.6. Oblique Therapeutics AB
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business Strategies
16.7. Revolution Medicines, Inc.
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT Analysis
16.7.7. Business Strategies
16.8. Silenseed LTD
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business Strategies
16.8.8. Company
Details
16.8.9. Company
Overview
16.8.10. Product
Offerings
16.8.11. Key
Developments
16.8.12. Financial
Analysis
16.8.13. SWOT Analysis
16.8.14. Business Strategies
16.9. Other
Market Participants
17. Key
Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
